Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention.

Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention.
复制标题

DOI:
10.1016/j.oraloncology.2013.12.024
复制
发表时间:
2014-10
期刊:
影响因子:
4.8
通讯作者:
William, William N., Jr.
William, William N., Jr.
中科院分区:
医学2区
文献类型:
--
作者:
Mak, Milena P.;William, William N., Jr.

文献摘要

参考文献

被引文献

相似文献

表皮生长因子受体(EGFR)与头颈部鳞状细胞癌(HNSCC)的癌变有关。目前,它是头颈部癌症中唯一的分子靶点,世界各地的监管机构批准了用于治疗晚期疾病的药物治疗干预措施。与正常黏膜相比,口腔恶性病变前EGFR蛋白表达增加,EGFR基因拷贝数增加。EGFR过表达或EGFR基因拷贝数增加的口腔癌前病变发生恶性转化的风险较高。在口腔恶性肿瘤前期临床前模型中抑制EGFR验证了该方法是降低口腔癌发病率的有效方法,并支持该策略在临床中的研究。EGFR靶向药物的临床试验,包括西妥昔单抗、厄洛替尼和万德替尼,目前正在进行中,其中一些有希望的初步结果。如果最终证明能降低口腔癌的风险,那么使用EGFR抑制剂进行化学预防可能会显著降低HNSCC的发病率和可能的死亡率。
The epidermal growth factor receptor (EGFR) has been implicated in head and neck squamous cell carcinoma (HNSCC) carcinogenesis. It is currently the only molecular target in head and neck cancers for which there are pharmacologic therapeutic interventions approved by regulatory agencies worldwide to treat advanced disease. Oral pre-malignant lesions have increased EGFR protein expression and increased egfr gene copy number compared to normal mucosa. Oral pre-malignant lesions with overexpression of EGFR or egfr gene copy number gain are at higher risk for malignant transformation. Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates this approach as an effective way to reduce the incidence of oral cancer, and supports investigation of this strategy in the clinic. Clinical trials with EGFR targeted agents, including cetuximab, erlotinib, and vandetanib, are currently under way, some with promising preliminary results. If ultimately shown to reduce the risk of oral cancer, chemoprevention with EGFR inhibitors may significantly reduce morbidity and possibly mortality from HNSCC.
DOI: 10.1093/jnci/90.20.1545
发表时间: 1998-10-21
期刊: JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子: --
作者:
Mao, L;Ei-Naggar, AK;Hong, WK
通讯作者: Hong, WK
DOI: 10.1158/1078-0432.ccr-05-1247
发表时间: 2005-12-01
影响因子: 11.5
作者:
Cohen, EEW;Kane, MA;Vokes, EE
通讯作者: Vokes, EE
DOI: 10.1016/s1470-2045(11)70034-1
发表时间: 2011-04-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Machiels, Jean-Pascal;Subramanian, Somasundaram;Clement, Paul M. J.
通讯作者: Clement, Paul M. J.
DOI: 10.1158/0008-5472.can-05-0628
发表时间: 2005-07-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Du, BH;Altorki, NK;Dannenberg, AJ
通讯作者: Dannenberg, AJ
DOI: 10.1056/nejmoa053422
发表时间: 2006-02-09
影响因子: 158.5
作者:
Bonner, JA;Harari, PM;Ang, KK
通讯作者: Ang, KK